Metformina + Sitagliptina Zentiva

Metformin Hydrochloride and Sitagliptin Hydrochloride, the active ingredient in Metformina + Sitagliptina Zentiva, is a biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults.

GNH USA supplies Metformina + Sitagliptina Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Sitagliptina Zentiva is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder requiring glycaemic control. - Type 2 diabetes mellitus: improves overall glycaemic control when added to diet and exercise. - Inadequate control with metformin alone: provides additional glucose‑lowering effect through DPP‑4 inhibition. - Adjunct therapy: used when further reduction of HbA1c is needed beyond monotherapy.

The combination may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: frequent loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headache. - Upper respiratory tract infection: cold‑like symptoms. - Hypoglycaemia (when used with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Pancreatitis: acute inflammation of the pancreas. - Hepatic failure: marked liver enzyme elevation. - Anaphylaxis: severe allergic response requiring immediate medical attention.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal function assessment: ensure adequate glomerular filtration before prescribing. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia. - Monitor for hypoglycaemia: especially when combined with insulin secretagogues. - Pregnancy and breastfeeding: weigh benefits against potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture.

Metformina + Sitagliptina Zentiva can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - IV contrast agents: may precipitate renal dysfunction and increase lactic acidosis risk. - Phenformin or other prohibited biguanides: additive risk of severe lactic acidosis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels. - Insulin or sulfonylureas: heightened risk of hypoglycaemia. - Alcohol excess: potentiates metformin‑related lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): can affect renal clearance of metformin. - ACE inhibitors or ARBs: may influence renal function, requiring dose adjustment. - NSAIDs: may reduce renal perfusion, increasing metformin exposure. - Warfarin: potential alteration of anticoagulant effect, monitor INR. - Beta‑blockers: may mask hypoglycaemia symptoms.